Evidence map›Paper›PMID 42540226›Full record

ArticleEULAR rheumatology open2026

Changes in serious infection and mortality among patients with ANCA-associated vasculitis during the COVID-19 pandemic: an interrupted time-series analysis of J-CANVAS.

Satoshi Omura, Takashi Kida, Daiki Nakagomi, Yoshiyuki Abe, Makoto Wada, Naoho Takizawa, Atsushi Nomura, Yuji Kukida, Naoya Kondo, Hirosuke Takagi and 27 more

Abstract read
In one paragraph

Article in EULAR rheumatology open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

37 authors.

Satoshi OmuraInflammation and Immunology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Takashi KidaInflammation and Immunology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Daiki NakagomiDepartment of Rheumatology, University of Yamanashi Hospital, Yamanashi, Japan.
Yoshiyuki AbeDepartment of Internal Medicine and Rheumatology, Juntendo University, Tokyo, Japan.
Makoto WadaCenter for Rheumatic Disease, Japanese Red Cross Society Kyoto Daiichi Hospital, Kyoto, Japan.
Naoho TakizawaDepartment of Rheumatology, Chubu Rosai Hospital, Aichi, Japan.
Atsushi NomuraImmuno-Rheumatology Center, St. Luke's International Hospital, Tokyo, Japan.
Yuji KukidaDepartment of Rheumatology, Japanese Red Cross Society, Kyoto Daini Hospital, Kyoto, Japan.
Naoya KondoDepartment of Nephrology, Kyoto Katsura Hospital, Kyoto, Japan.
Hirosuke TakagiDepartment of Hematology and Rheumatology, Kagoshima University Hospital, Kagoshima, Japan.
Koji EndoDepartment of General Internal Medicine, Tottori Red Cross Hospital, Tottori, Japan.
Shintaro HirataDepartment of Clinical Immunology and Rheumatology, Hiroshima University Hospital, Hiroshima, Japan.
Naoto AzumaDepartment of Diabetes, Endocrinology and Clinical Immunology, Hyogo Medical University School of Medicine, Hyogo, Japan.
Tohru TakeuchiDepartment of Internal Medicine (IV), Osaka Medical and Pharmaceutical University, Osaka, Japan.
Shoichi FukuiDepartment of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
Kazuro KamadaDepartment of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Hokkaido, Japan.
Ryo YanaiDivision of Rheumatology, Department of Medicine, Showa Medical University School of Medicine, Tokyo, Japan.
Yusuke MatsuoDepartment of Rheumatology, Tokyo Kyosai Hospital, Tokyo, Japan.
Yasuhiro ShimojimaDepartment of Medicine (Neurology and Rheumatology), Shinshu University School of Medicine, Nagano, Japan.
Ryo NishiokaDepartment of Nephrology and Rheumatology, Graduate School of Medical Science, Kanazawa University, Ishikawa, Japan.
Ryota OkazakiDivision of Respiratory Medicine and Rheumatology, Department of Multidisciplinary Internal Medicine, Faculty of Medicine, Tottori University, Tottori, Japan.
Tomoaki TakataDivision of Gastroenterology and Nephrology, Tottori University, Tottori, Japan.
Mayuko MoriyamaDepartment of Rheumatology, Shimane University Faculty of Medicine, Shimane, Japan.
Ayuko TakataniRheumatic Disease Center, Sasebo Chuo Hospital, Nagasaki, Japan.
Yoshia MiyawakiDepartment of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.
Tsuyoshi ShiraiDepartment of Rheumatology, Tohoku University Hospital, Miyagi, Japan.
Hiroaki DobashiDivision of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa University, Kagawa, Japan.
Takafumi ItoDivision of Nephrology, Department of Internal Medicine, Teikyo University Chiba Medical Center, Chiba, Japan.
Isao MatsumotoDepartment of Rheumatology, Institute of Medicine, University of Tsukuba, Ibaragi, Japan.
Toshihiko TakadaDepartment of General Medicine, Shirakawa Satellite for Teaching And Research (STAR) Fukushima Medical University, Fukushima, Japan.
Toshiko Ito-IharaThe Clinical and Translational Research Center, University Hospital, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Nobuyuki YajimaDivision of Rheumatology, Department of Medicine, Showa Medical University School of Medicine, Tokyo, Japan.
Takashi KawaguchiDepartment of Clinical Assessment, Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan.
Kazuki FujiokaInflammation and Immunology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Takahiro SenoInflammation and Immunology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Masataka KohnoInflammation and Immunology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Yutaka KawahitoInflammation and Immunology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: In antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, infection risk exceeds that of the general population, and infection is a leading cause of death. However, the impact of the COVID-19 pandemic on serious infections and mortality in this population remains uncertain. Methods: This observational study used data from the nationwide registry in Japan (Japan Collaborative Registry of ANCA-Associated Vasculitis), which includes patients with newly diagnosed and relapsed ANCA-associated vasculitis from 29 sites between January 2017 and March 2023. The primary outcome was serious infection requiring hospitalisation; the secondary outcome was all-cause mortality. The impact of COVID-19 was estimated using an interrupted time-series analysis, with the boundary between April and May 2020 as the change point, following the first declaration of a state of emergency in Japan. Monthly incidence rates were modelled using segmented Poisson regression. Rate ratios (RRs) for level and slope changes with 95% CI were reported. Several sensitivity analyses were performed. Results: Among 1064 patients, total follow-up was 37,535 person-months; 205 serious infections and 96 deaths occurred. For serious infection, the level-change RR was 0.54 (95% CI: 0.31-0.94) and the slope-change RR was 1.01 (0.98-1.04). For all-cause mortality, the level-change RR was 0.35 (0.12-0.98) and the slope-change RR was 1.001 (0.94-1.06). Findings were robust across sensitivity analyses. Conclusions: Immediately after the onset of the COVID-19 pandemic, a clear reduction in serious infections and mortality was observed without major changes in patient characteristics. These findings may reflect the impact of social and personal infection control measures.

Identifiers

PMID42540226
PMCPMC13425167

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.